Attendee search 

As the first professional injection producer in China,Shanghai Haipu Pharmaceutical factory was founded in 1925 and renamed as Shanghai Xudong Haipu Pharmaceutical Co.,Ltd after jointed with Taiwan Tungyang International Co.,Ltd in 1993.The company has developed for more than 90 years so far, and has accumulated rich experience in production and brand awareness.

Mainly for investment services and project indUnited Statestrialization

广东省钟南山医学基金会是在名誉理事长钟南山院士支持下，由呼吸疾病国家重点实验室产学研基地、国家呼吸系统疾病临床医学研究中心产学研分中心、广州医科大学国家大学科技园发起，于2011年7月5日经广东省民政厅批复成立的非公募基金会。

证券公司研究所

混合所有制企业。

We are the flagship subsidiary of China Resources Group, engaging in the research and development, manufacturing, distribution and retail of a broad range of pharmaceutical and healthcare products.In 2018, our total revenue is HK$ 189.7 billion.
Currently CR Pharma Group is one of the TOP 3 pharmacetucial group in China, and our core competences is capabilities are marketing&sales(3000+ Sales Reps for RX and 3000+ Sales Reps for OTC and healthcare products, local Regulatory Affairs(Dedicated RA team), and great manufacturing facilities(40+ manufacturing sites in China, including API and finished products of all dosage forms, 4 sites are approved by US FDA and EMEA).
As a listed company in HK, CR Pharma has estalished consodiated business reputation in healtcare industry and capital market. And currently, nearly all top 50 MNC pharmacetical companies are our business partner in China, and business scope includes JV, Licensing, Commercial Distribution.

Chengdu Jian River Pharmaceutical Co., Ltd. was established in 2019 with a registered capital of 20 million yuan. The establishment of jianRiver serves Sichuan Development (Holdings) Co., Ltd. and the people's Government of Pengzhou City to set up a "Pengzhou Fund". For Tianfu traditional Chinese Medicine City in the global recruitment and incubation of pharmaceutical projects, through docking funds to provide professional management and services to provide support for the growth of the project. As the main body of the construction and operation of the innovation incubator in Pengzhou Tianfu traditional Chinese Medicine City, relying on rich project channel resources and professional service team, it is committed to helping excellent modern Chinese medicine research and development enterprises, new drug research and development enterprises, cutting-edge biotechnology companies, medical device companies and large health industry related enterprises to accurately land in Pengzhou, through the whole industry chain services such as professional incubation acceleration, achievement transformation and financial investment. Promote the rapid development of innovative start-up enterprises. Adhering to the concept that "high-quality projects are the foundation of industrial development, and first-class talents are the core force of project growth", Jian River will gather high-quality projects to jointly build a high-quality medicine and large-scale health project incubation base in Pengzhou. Help more outstanding top entrepreneurial talents to realize their entrepreneurial ideals.

隶属于浙江亚太药业股份有限公司，位于武汉光谷，从事新药研发、仿制药开发、临床研究服务等

license in innovative medicine and 505(b)(2),R&D generic drugs

Founded in 2005, Baiyu is dedicated to R&D, manufacturing and marketing high-quality pharmaceutical products and APIs to all patients. As an innovation-based pharmaceutical company, we are specializing in chemical/botanical/biological medicinal products, especially ginkgo pharmaceutical products. And in 2020, aiming to protect everyone’s healthcare, Baiyu has built own subsidiary to produce high quality of Personal Protective Equipment to worldwide market.

With more than 1,300 employees and 8 wholly owned subsidiaries, Baiyu has a rich pipeline of products launched for neuropsychiatric, cardio-cerebrovascular, anti-tumor, respiratory, digestive, anti-infective areas along with many products under development. And Ginkgolide injection is the first innovative botanical injectable approved since the implementation of Drug Registration Regulation (2007), of which the active ingredient contents reach up to 99%.

Currently, several production lines have obtained GMP certificates, and new factories meeting EU&US GMP requirements with fully automatic and intelligent operations have been built to accelerate Baiyu’s globalization process.